Industrial bioscience firm Amyris (Emeryville, California) announced on Monday that it has entered into its first product development and production agreement with DSM.
The agreement covers an undisclosed food and nutrition molecule for which DSM is a major market provider. DSM will fund technology development, and Amyris will scale and supply the ingredient in the long-term.
The agreement is expected to be the first of many such collaborations, Amyris says. In May, DSM made an initial equity investment in Amyris of $25 million for a shareholding of about 12%. Subject to certain conditions, DSM could invest an additional $25 million in the company within 90 days of the first tranche if approved by DSM’s board. As part of the deal, DSM and Amyris agreed to collaborate on a number of short- to medium-term product development and production opportunities using Amyris’s yeast-based strain engineering platform.
By Rebecca Coons
Source: Chemical Week
Neste Corporation’s Board of Directors has appointed Heikki Malinen, M.Sc. (Econ.), MBA (Harvard) as the President and CEO of Neste as of 2 November 2024, at the latest. Malinen joins Neste from Outokumpu Corporation where he has held the position of President and CEO since 2020.
Petrochemicals company Sasol has announced that CFO and executive director Hanré Rossouw will step down from his position, effective October 31. Sasol has started the process to appoint a successor. Rossouw will still oversee the publication of Sasol’s reports for the financial year ending June 30, to allow for a structured handover period.
Chemours announced its CFO Jonathan Lock has resigned from all positions within the company, according to an SEC 8-K filing on April 23. The resignation comes in the aftermath of the company announcing that Lock, former CEO Mark Newman, and principal accounting officer Camela Wisel, had been placed on administrative leave.
